PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER		see Form PCT/ISA/220	
29725P WO	71011011		Il as, where applicable, item 5 below.	
International application No.	International filing date (day/month/year)		(Earliest) Priority Date (day/month/year)	
PCT/EP2004/003238	26/03/2004		28/03/2003	
Applicant				
Drown and reading and	D.T.O.M.T.GV.DV.O.T.O.GV.DV.			
BIOPHARM GESELLSCHAFT ZUR	BIOTECHNOLOGISCHEN			
This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.				
This international Search Report consists	of a total of she	ets.		
X It is also accompanied by	a copy of each prior art document ci	ed in this	report.	
			sis of the international application in the	
	ess otherwise indicated under this ite			
The international state this Authority (Rul		fa transl	ation of the international application furnished to	
b. With regard to any nucleo	etide and/or amino acid sequence	disclosed	in the international application, see Box No. I.	
2. Certain claims were four	2. Certain claims were found unsearchable (See Box II).			
3. Unity of invention is lack	king (see Box III).			
4. With regard to the title ,				
X ,the text is approved as sui	bmitted by the applicant.			
the text has been establish	ned by this Authority to read as follow	rs:		
5. With regard to the abstract,				
the text is approved as sul				
the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.				
6. With regards to the drawings,				
a. the figure of the drawing s to be p	ublished with the abstract is Figure N	o. <u>1</u>		
as suggested by the	• •			
	s Authority, because the applicant fai	_		
	as selected by this Authority, because this figure better characterizes the invention. b. none of the figures is to be published with the abstract.			

Form PCT/ISA/210 (first sheet) (January 2004)

International application No.

INTERNATIONAL SEARCH REPORT

PCT/EP2004/003238

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

The present invention relates to an osteoinductive material comprising a matrix material with morphogenetic protein(s) absorbed on inner or outer surfaces of this matrix material, wherin the osteoinductive material is obtainable by contacting the matrix material and the morphogenic protein(s) under conditions of pH and ionic concentration to keep protein stable and dissolved in a solution

until dried and thereby allowing that the matrix material becomes evenly coated with the morphogenic protein(s)

Form PCT/ISA/210 (continuation of first sheet (3)) (January 2004)

International application No. PCT/EP2004/003238

INTERNATIONAL SEARCH REPORT

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 26-29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest
No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP2004/003238

A. CLASSII IPC 7	FICATION OF SUBJECT MATTER A61L27/34 A61L27/56 C07K14/	475			
According to International Patent Classification (IPC) or to both national classification and IPC					
	SEARCHED				
Minimum do IPC 7	ocumentation searched (classification system followed by classification $A61L - C07K$	tion symbols)			
	tion searched other than minimum documentation to the extent that				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ					
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.		
Х	US 6 118 043 A (DINGELDEIN ELVII 12 September 2000 (2000-09-12) claims 1,7-13,19	RA ET AL)	1-29		
А	WO 94/15653 A (GENENTECH INC) 21 July 1994 (1994-07-21) claims 1-4,9,10,17		1–29		
			(
Fur	ther documents are listed in the continuation of box C.	X Patent family members are listed	in annex.		
° Special c	ategories of cited documents:	"T" later document published after the int	emational filing date		
"A" document defining the general state of the art which is not considered to be of particular relevance invention			n the application but neory underlying the		
"E" earlier document but published on or after the international filing date "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken along the cannot be considered.					
which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such document.					
other means ments, such combination being obvious to a person skilled in the art. ments, such combination being obvious to a person skilled in the art.					
Date of the actual completion of the international search Date of mailing of the international search					
2	22 September 2004	04/10/2004			
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 Authorized officer					
ļ	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Heck, G			

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/003238

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 6118043		12-09-2000	DE	4121043 A1	07-01-1993
			AT	176161 T	15-02-1999
			ΑU	652839 B2	08-09-1994
			ΑU	1854692 A	07-01-1993
			CA	2072244 A1	27-12-1992
			CZ	9201946 A3	13-01-1993
			DE	59209624 D1	11-03-1999
			EP	0520237 A2	30-12-1992
			ES	2128330 T3	16-05-1999
			HU	65499 A2	28-06-1994
			ΙE	922067 A1	30-12-1992
			JP	7171211 A	11-07-1995
			JP	2003093495 A	02-04-2003
			MX	9203253 A1	31-03-1994
			NO	922511 A	28-12-1992
			PL	295001 A2	28-12-1992
			RU	2062622 C1	27-06-1996
			ZA	9204780 A	28-04-1993
WO 9415653	Α	21-07-1994	AT	153535 T	15-06-1997
			AU	671721 B2	05-09-1996
			ΑU	6026294 A	15-08-1994
			CA	2151486 A1	21-07-1994
			DE	69403439 D1	03-07-1997
		•	DE	69403439 T2	23-10-1997
			DK	679097 T3	22-12-1997
			EΡ	0679097 A1	02-11-1995
			ES	2105641 T3	16-10-1997
			GR	3024277 T3	31-10-1997
			JP	3347144 B2	20-11-2002
			JP	8505548 T	18-06-1996
			WO	9415653 A1	21-07-1994
			US	5422340 A	06-06-1995

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY WRITTEN OPINION OF THE see form PCT/ISA/220 INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing (day/month/year) see form PCT/ISA/210 (second sheet) Applicant's or agent's file reference FOR FURTHER ACTION see form PCT/ISA/220 See paragraph 2 below International filing date (day/month/year) Priority date (day/month/year) International application No. 28.03.2003 26.03.2004 PCT/EP2004/003238 International Patent Classification (IPC) or both national classification and IPC A61L27/34, A61L27/56, C07K14/475 Applicant BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN... This opinion contains indications relating to the following items: 1. Box No. I Basis of the opinion Box No. II **Priority** Non-establishment of opinion with regard to novelty, inventive step and industrial applicability ☑ Box No. III ☐ Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial ☑ Box No. V applicability; citations and explanations supporting such statement ☐ Box No. VI Certain documents cited Certain defects in the international application ☐ Box No. VII ☐ Box No. VIII Certain observations on the international application 2. **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notifed the International Bureau under Rule 66.1 bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:



European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016 Authorized Officer

Heck, G

Telephone No. +31 70 340-3288



10/550958

JC09 Rec'd PCT/PT0 28 SEP 2005 International application No. PCT/EP2004/003238

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

	Box	No	. I Basis of the opinion		
1.	With regard to the language , this opinion has been established on the basis of the international application in the language in which it was field, unless otherwise indicated under this item.				
		lan	s opinion has been established on the basis of a translation from the original language into the following guage , which is the language of a translation furnished for the purposes of international search der Rules 12.3 and 23.1(b)).		
2.	. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:				
	a. ty	pe (of material:		
		3	a sequence listing		
		J .	table(s) related to the sequence listing		
	b. fo	rma	at of material:		
	D	3	in written format		
			in computer readable form		
	c. tii	ne d	of filing/furnishing:		
	٥	₫ (contained in the international application as filed.		
	[) 1	filed together with the international application in computer readable form.		
] 1	furnished subsequently to this Authority for the purposes of search.		
3.		has cop	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto been filed or furnished, the required statements that the information in the subsequent or additional lies is identical to that in the application as filed or does not go beyond the application as filed, as propriate, were furnished.		
4.	Add	ition	al comments:		

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/EP2004/003238

Вс	x No. II	Priority				
1. ☑ The following document has not been furnished:						
	\boxtimes	copy of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(a)).				
		translation of the earlier application whose priority has been claimed (Rule 43bis.1 and 66.7(b)).				
		quently it has not been possible to consider the validity of the priority claim. This opinion has neless been established on the assumption that the relevant date is the claimed priority date.				
2. 🗆	has be	pinion has been established as if no priority had been claimed due to the fact that the priority claim en found invalid (Rules 43 <i>bis</i> .1 and 64.1). Thus for the purposes of this opinion, the international ate indicated above is considered to be the relevant date.				
3. Ac	3. Additional observations, if necessary:					

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/EP2004/003238

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:					
	the entire international application,				
\boxtimes	claims Nos. 26-29				
because:					
⊠	the said international application, or the said claims Nos. 26-29 relate to the following subject matter which does not require an international preliminary examination (specify):				
	see separate sheet				
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
	no international search report has been established for the whole application or for said claims Nos.				
	the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
	the written form		has not been furnished		
			does not comply with the standard		
	the computer readable form		has not been furnished		
			does not comply with the standard		
	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.				
	☐ See separate sheet for further details				

Box No. V Reasoned statement under Rule 43*bis*.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Yes: Claims 1-25

No: Claims -

Inventive step (IS) Yes: Claims -

No: Claims 1-25

Industrial applicability (IA) Yes: Claims 1-25

No: Claims -

2. Citations and explanations

see separate sheet

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Since claims 26-29 are directed to a method of treatment of the human or animal body by surgery/therapy, they relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. For the assessment of the subject-matter of present claims 26-29 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States.

Therefore, no opinion will be formulated with respect to the subject-matter of claims 26-29 (Article 34(4)(a)(i) PCT).

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The following document (D1) cited in the International search report is referred to in this communication; the numbering will be adhered to in the rest of the procedure:

D1: US 6,118,043 A (Nies B. et al.)

Novelty

Document D1 discloses (cf. claims 1, 7-13, 19) a bone replacement material comprising a porous matrix and fibroblast growth factor (FGF) adsorbed thereon. The material is prepared by impregnating the porous matrix with a solution of FGF followed by drying. The subject-matter of claims 1-25 of the present application differs from the disclosure of D1 by the choice of pH and ionic concentration of the morphogenetic protein solution and is therefore novel according to Article 33(2) PCT.

Inventive Step

Document D1, which is considered to represent the most relevant prior art, discloses (claims 1, 7-13, 19) the impregnation of porous implants with a solution of 50 μ g FGF to provide a bone replacement material having a biological activity as close as possible to that of endogenous bone transplantation.

In view of D1, the objective technical problem underlying the present application can be formulated as to provide osteoinductive matrix materials for use in the pharmaceutical field which are homogeneously coated with morphogenetic proteins.

The solution proposed in the present application is a porous osteoinductive material comprising a matrix material having morphogenetic protein(s) adsorbed on inner or outer surfaces thereon, which can be obtained by selecting a pH and an ionic concentration of the solution that avoid precipitation of the morphogenetic proteins.

The expression "contacting the matrix material and the morphogenetic protein(s) under suitable conditions to keep the protein stable and dissolved in a solution until dried" in claim 1 refers to a desirable result without indicating the technical features necessary to obtain it. This leads to a lack of clarity of the claim (Article 6 PCT). The technical contribution of the present invention is not the theoretical finding that a complete dissolution of the morphogenetic protein allows a more homogeneous coating of the matrix material, but the realisation how to enhance both protein stability and solubility during the coating process, which is attainable by selection and control of the pH and low ionic concentrations using suitable buffers/solvents or specific additives (cf. description, p. 7, l. 28-31 and p. 9, l. 4-14). These features should be included in claim 1 to make the claim clear.

Due to the lack of the above-mentioned essential features in claim 1, the subject-matter of claims 1-25 is at present not considered to involve an inventive step according to Article 33(3) PCT. Should the Applicant, however, include those features into claim 1, the following statement would apply:

Since the relation between the pH and low ionic concentration of the morphogenetic protein solution on the one hand and the solubility of the morphogenetic proteins on the other hand is unexpected and allows to obtain a more homogeneous coating of the matrix material, the subject-matter of claims 1-25 is based on an inventive activity according to Article 33(3) PCT.